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Abstract
Genome-wide linkage and association studies have uncovered variants associated with sarcoidosis,
a multi-organ granulomatous inflammatory disease. African ancestry may influence disease
pathogenesis since African Americans are more commonly affected by sarcoidosis. Therefore, we
conducted the first sarcoidosis genome-wide ancestry scan using a map of 1,384 highly ancestry
informative single nucleotide polymorphisms genotyped on 1,357 sarcoidosis cases and 703
unaffected controls self-identified as African American. The most significant ancestry association
was at marker rs11966463 on chromosome 6p22.3 (ancestry association risk ratio (aRR)= 1.90;
p=0.0002). When we restricted the analysis to biopsy-confirmed cases, the aRR for this marker
increased to 2.01; p=0.00007. Among the eight other markers that demonstrated suggestive
ancestry associations with sarcoidosis were rs1462906 on chromosome 8p12 which had the most
significant association with European ancestry (aRR=0.65; p=0.002), and markers on
chromosomes 5p13 (aRR=1.46; p=0.005) and 5q31 (aRR=0.67; p=0.005), which correspond to
regions we previously identified through sib pair linkage analyses. Overall, the most significant
ancestry association for Scadding stage IV cases was to marker rs7919137 on chromosome
10p11.22 (aRR=0.27; p=2×10−5), a region not associated with disease susceptibility. In summary,
through admixture mapping of sarcoidosis we have confirmed previous genetic linkages and
identified several novel putative candidate loci for sarcoidosis.
Introduction
Sarcoidosis, a multiorgan granulomatous inflammatory disease, likely results from an
exaggerated T cell response to an airborne antigen 1. The first genome-wide linkage study of
sarcoidosis in 63 German families found linkage of sarcoidosis to chromosome 6p212.
Subsequently, a novel sarcoidosis risk variant at rs2076530 was identified, which predicted
a premature splice site at exon 5 of the class II gene BTNL2, a B7 family co-stimulatory
molecule3. The increased sarcoidosis risk associated with this variant was replicated in
another German population 4, by our group in European Americans 5, and in a Dutch and
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British population 6. We also studied variation at exon 5 of BTNL2 in African-American
sarcoidosis cases and controls and found variants other than rs2076530 associated with
sarcoidosis 5.
Additional genome-wide studies have confirmed that sarcoidosis is a complex genetic
disease with multiple loci having modest effects. In the Sarcoidosis Genetic Analysis
(SAGA) study 7 of 516 African-American sib pairs with at least one affected sib and 359
pairs with both sibs affected, our most significant linkage peaks spanned chromosomes
5p15.2 and 5q11.2 8. A second analysis of this same study population using disease sub-
phenotypes found that chest radiographic resolution had one of the highest LOD scores
among the pulmonary and extrathoracic involvement phenotypes analyzed 9. The latest
evidence for a genetic predisposition to sarcoidosis comes from the first sarcoidosis
genome-wide association scan (GWAS), conducted in a German population, that had its
most significant disease association map to Annexin A11 (ANXA11), a gene with complex
and essential functions in several biological pathways, including cell apoptosis and
proliferation 10.
Study of the genetics of sarcoidosis in African Americans, who are more commonly and
severely affected by this disease 11, suggests that focusing on genes of African ancestry may
uncover novel risk variants. A higher incidence of sarcoidosis in African Americans
compared with whites has long been noted 12,13 with an over three-fold increased incidence
of sarcoidosis in African Americans compared with whites, 35.5 per 100,000 vs. 10.9 per
100,000 11. Other studies outside of the United States that compared sarcoidosis incidence
in populations of West African ancestry with whites further support a role of African genes
in sarcoidosis susceptibility. In South Africa, sarcoidosis incidence was reported as 23.2 per
100,000 in blacks and 3.7 per 100,000 in Whites 14. In Great Britain, Edmondstone and
Wilson 15 reported an annual sarcoidosis incidence of 19.8 per 100,000 in blacks and 1.5
per 100,000 in whites. The eight to ten fold higher incidence of sarcoidosis in blacks in the
South African and Great Britain studies is notable because of decreased European ancestry
in these two populations compared with African Americans. Average European admixture
proportions are about 10 percent in African Caribbeans living in Great Britain compared
with 18 percent for African Americans 16. Among the disease outcomes in sarcoidosis that
have a strong link with African ancestry, persistence of radiographic evidence for disease
among patients of African descent appears to be a consistent finding 15. In a multi-site case
control study, after two years of observation, African-American cases were 80% more likely
to have a worsening chest x-ray, although this finding was not statistically significant 17. In
general, self reported African ethnicity is strongly related to increased sarcoidosis risk and
more severe disease outcomes.
The recent development of genome-wide ancestry informative marker panels 18,19 now
makes scanning the genome for disease genes linked to ancestry in African-American
populations feasible. Mapping by admixture linkage disequilibrium (MALD) involves
screening the genome of individuals of mixed ancestry who have a disease or trait of interest
for chromosomal regions that have a greater percentage of alleles than expected from a
parental population. The theory behind MALD is that affected individuals are more likely to
carry alleles from the higher risk parental population in chromosomal segments that also
harbor disease loci. Advantages to using admixture mapping over genome-wide association
mapping include the ability to find effects where there is marked allelic heterogeneity across
ethnic groups 20 or where a risk allele is fixed in either parental population. Admixture
mapping can also more readily detect risk effects emanating from genes due to rare copy
number variants than can a dense SNP map relying only on allelic association. MALD in
African-American populations has been used to localize susceptibility loci for prostate
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cancer 21, kidney disease 22, peripheral artery disease 23, type 2 diabetes 24, obesity 25,26,
interleukin-6 levels 27 and blood lipid levels 28.
To determine whether African ancestry is linked with sarcoidosis genetic susceptibility, we
conducted a whole genome admixture scan using a panel of ancestry-informative markers in
a large sample of African-American sarcoidosis cases and unaffected controls. We
hypothesized that ancestry-linked genes may predispose to either disease susceptibility and/
or severity, as measured by radiographic progression.
Results
Overall Results
The MALD scan estimated associations between increased or decreased African ancestry
based on 1,384 SNPs typed on a sample of African-American unrelated sarcoidosis cases
(n=1,026) and controls (n=316). The mean African ancestry estimate of the analytic sample
was 82.6% with sarcoidosis cases having a slightly higher level of African ancestry than
controls (82.9% vs. 81.5%; p=0.03). We detected nine distinct chromosomal regions that
had suggestive ancestry associations with sarcoidosis: four with excess African and five
with excess European ancestry (table 1). These regions were identified based on affected-
only test p values < 0.01 and the same ancestry differential based on the ancestry association
test (figure 1). For consistency, the ancestry risk ratios (aRRs) estimated from the more
powerful affected-only test are reported in the text. While none met the genome-wide
significance level of 10−5 29, the most prominent ancestry linkage peak located at
chromosome 6p24.3-6p12.1 had as its most significant marker rs11966463 with an aRR of
1.90 and a Z score of 3.78 (p=0.0002), indicative of increased risk of sarcoidosis associated
with excess African ancestry at this locus. The second most prominent peak was on
chromosome 17p13.3-17p13.1 with marker rs8070464 having an aRR of 1.68 (Z = 3.51;
p=0.0005) also indicative of increased risk of sarcoidosis associated with excess African
ancestry. The other two regions that showed excess African ancestry among sarcoidosis
cases were chromosomes 4q31.21-4q34.1 and 5p13.3-5p13.2. The five regions that showed
excess European ancestry among sarcoidosis cases were chromosomes 2p13.3-2p13.1,
2q35-2q26.3, 5q23.1-5q31.2, 6q23.3-6q25.2 and 8p21.3-8p11.21. Chromosome
8p21.3-8p11.21 was the most significant of the five (p=0.002), but all were comparable in
magnitude. In general, ancestry association Z-scores were, as expected, of lower magnitude
than affected-only test Z scores, but in the same direction with the same peak SNPs (figure
1). Of note, was a 10 mB region on chromosome Xq24-Xq25, which had the most
statistically significant affected-only test p value, but none of the SNPs in this peak attained
our ancestry association p value criterion of 0.05. Analyses were rerun for the subset of 910
unrelated cases with a definite (i.e., histologically confirmed) diagnosis of sarcoidosis, and
the results were nominally changed (table 2). In these analyses, the most significant finding
remained at rs11966463 and increased in significance to p=0.00007. Results in the definite
case group for the other eight regions were nominally changed with the possible exception
of chromosome 8p21.3-11.21, where the aRR increased from 0.67 to 0.77 and the p value
increased from 0.003 to 0.06.
Results in Demographic and Phenotypic Subsets
Of the nine sex-specific aRRs shown in table 3, only the sex-specific aRRs in the
5q23.1-5q31.2 region were statistically significantly different from each other (p=0.003).
Female cases had ancestry risk ratios of greater magnitude than male cases for six of the
nine ancestry peaks, with the only exceptions being chromosomes 5p13.3-5p13.2,
6q23.3-6q25.2, and 17p13.3-17p13.1 where the female-specific risk ratios were of slightly
lower magnitude than for males. For four of the six peaks where the female-specific aRR
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was of greater magnitude (chromosomes 2q35-2q36.3, 4q31.21-4q34.1, 5q23.1-5q31.2 and
6p24.3-6p12.1), the excess ancestry risk appeared to be almost exclusive to female subjects.
In addition to the loci identified in the unstratified analysis, marker rs2476230 on
chromosome 13q32.2-13q33.3 had an elevated aRR (1.60; p=0.003) only in female subjects
and marker rs1131877 on chromosome 14q32.2-14q32.33 had an elevated aRR (2.63;
p=0.002) only in male subjects.
When stratifying cases by chest radiographic phenotype and analyzing using the affected-
only test, seven additional distinct ancestry peaks that were detected, including
chromosomes 2p24.3-2p16.1, 4q21.1-4q24, 10p12.2-10q11.23, 16q22.1-1623.2,
18p11.32-18p11.31, 18q23 and 19p12-19q13.41 (table 4). Of the nine original ancestry
peaks found in the full case sample, four (2p13.3-2p13.1, 5p13.3-5p13.2, 6q23.3-6q25.2 and
17p13.3-17p13.1) had aRRs of much greater magnitude and more significant associations in
the more severe Scadding stage IV case group, despite this case subset being less than 20
percent of the size of the full case sample. A formal test for heterogeneity revealed three loci
with significant differences in aRRs between the extreme radiographic phenotypes of stage
IV sarcoidosis and radiographically resolved disease (table 5). All three loci were European
ancestry-associated loci in the full case group with much stronger associations with
European ancestry in stage IV cases. For example, in stage IV chest radiograph cases,
chromosome 10p11.22 had the aRR of greatest magnitude (aRR=0.27; p=2 × 10−5) for any
of the phenotypic subsets analyzed.
Finally, we ran several validity checks on our results. The main analysis for disease
susceptibility was redone using ANCESTRYMAP 30 with resulting African and European
ancestry associations virtually identical to what we found using ADMIXMAP. We also
redid the main analysis for 100 resamples of our full dataset, in which we relaxed the
sampling criteria such that any individual irrespective of affection status could be randomly
selected from a family. Analysis of these 100 different samples of unrelated individuals
showed essentially the same patterns of ancestry associations across the genome.
Exclusion Map
We prepared an exclusion map for the inclusive (definite and highly probable; n=1,026
cases) case definition (supplementary figure 1) based on the affected-only test results. At
least 90% of the genome can be excluded as having a European effect on risk of 2.12 or
more, and at least 90% can be excluded as having an African effect on risk of 2.10 or more.
Further, among the subset of definite cases (n=910), at least 90% of the genome can be
excluded as having a European effect on risk of 2.23 or more, and at least 90% can be
excluded as having an African effect on risk of 2.19 or more. The power of the subanalysis
for definite cases is less than that for all cases because of the smaller sample size.
Discussion
We used admixture mapping to search the genome for sarcoidosis susceptibility genes
linked to ancestry in African Americans. The chromosomal regions we identified
complement and confirm previous genomic regions identified by past genome-wide linkage
31,8 and association 10 studies in African Americans and whites. The chromosome
5p13.3-5p13.2, 5q23.1-5q31.2 ancestry linkage signals overlap with the chromosome 5
sarcoidosis linkages we previously reported in African American sib pairs 8. Moreover, the
chromosome 5p and 5q regions have also been implicated in Crohn’s disease. The
chromosome 5p13 region linked to Crohn’s disease has been characterized as a 1.25
megabase gene desert, but disease associated variants in this region are associated with
expression levels of PTGER4 32, the closest gene that maps to this region. Chromosome
5q31 contains the cytokine gene cluster with unique variants associated with Crohn’s
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disease 33 and psoriasis 34,35. The chromosome 6p24.3-6p12.1 ancestry peak overlaps with
the chromosome 6p21 sarcoidosis linkage signal originally reported by Schurmann et al. 31.
We also found novel regions containing putative sarcoidosis susceptibility loci on
chromosomes 2p13.3-2q12.1, 2q35-2q36.3, 4q31.21-4q34.1, 6q23.3-6q25.2,
8p21.3-8p11.21 and 17p13.3-17p13.1.
Of the nine ancestry linkage peaks we identified in the overall risk analysis, the African
ancestry peak on chromosome 6p24.3-6p12.1 was the most statistically significant (p=7 ×
10−5 for rs11966463 in definite cases) and was close to the genome-wide significance level
of 10−5 for admixture mapping 29. This region spans 50 megabases and includes the entire
major histocompatibility complex on chromosome 6p21. Variants of the class II HLA-DR
and DQ genes are located in this region and known to be associated with sarcoidosis
susceptibility and progression 36,37,38,39. In addition, the exon 5 SNP rs2076530 of the
BTNL2 gene 200 kilobases telomeric from HLA-DRB1 was shown to be the primary
disease-associated variant in a German sample that was driving the linkage signal previously
identified in this sample 3. Increased allelic heterogeneity across the HLA region in African
Americans 40,41 was the likely explanation for why we replicated this association in the
ACCESS white case-control sample but not in two different African-American samples 5.
The numerous previously reported associations of genetic variation in the HLA region with
sarcoidosis and the linkage to this region suggest that the prominent African ancestry peak at
6p22 we observed in African-American sarcoidosis cases could be due to underlying disease
causing genes in the HLA region.
To appropriately estimate disease-ancestry linkage on the X chromosome, we had to account
for the known unequal contribution of male and female European founders to the present
day African-American gene pool 42,43. In our study sample, we estimated ψ, the female/
male odds ratio for European versus African founders, to be 3.1, which falls within the range
of ψ estimates (2.3-4.3) derived from European admixture estimates based on mitochondrial
and Y chromosome lineages in other African-American samples. Despite the incorporation
of ψ into the estimation of X chromosome admixture proportions, we still found two broad
peaks on the X chromosome at which the observed African ancestry on the X chromosome
of cases was much higher than the expected value given autosomal admixture proportions
and ψ. A similar excess of African ancestry was observed over the same regions in controls,
however, suggesting that the frequency of African ancestry in these regions is higher than
elsewhere as a result of drift or selection for African derived DNA on the X chromosome in
African Americans rather than a true disease association.
We failed to find evidence for increased African or European ancestry influencing
sarcoidosis susceptibility on chromosome 10q22.3. This is the region containing the
ANXA11 (annexin A11) gene with a common nonsynonymous SNP (rs1049550, T > C,
R230C) found to be the most strongly associated sarcoidosis SNP in a German GWAS of
sarcoidosis susceptibility 10. None of the ANAX11 sarcoidosis associated variants show
significant allelic diversity between African and European populations. This highlights the
main limitation of admixture mapping in that putative disease risk variants with similar
frequencies in the ancestral African and European populations that comprise the current day
African-American population are undetectable by admixture mapping.
A female preponderance in sarcoidosis cases is well documented 11,44 and some evidence
suggests that female cases may also incur greater granuloma burden in early stage disease
45. In terms of underlying genetic liability, polygenic complex disease theory is that
individuals with a lower population risk who contract the disease in question (e.g., males for
sarcoidosis) have on average more genetic liability 46. We previously found a greater
familial risk associated with African-American male sarcoidosis cases compared with
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females 47, but the ACCESS case-control study consisting of both white and African-
American subjects found no difference in sex-specific familial risk 48. Others have reported
sex-specific effects of alleles predisposing to sarcoidosis susceptibility or disease
manifestations 49,50,51,52. Our sex-stratified analyses showed that some ancestry linkage
signals were consistent for males and females, whereas others were sex-specific. Ancestry
signals on chromosomes 2q35-2q36.3, 4q31.21-4q34, 5q23.1-5q31.2, 6p24.3-6p12.1, and
13q32.2-13q33.3 appeared to be exclusive to females, whereas only one significant signal
was exclusive to males, on chromosome 14q32.2-14q32.33, however the aRR at this locus at
2.63 was of the greatest magnitude of the sex-specific ancestry signals. Given the 3:1 ratio in
female to male sarcoidosis cases in our analytic dataset, it is unclear whether the abundance
of significant ancestry signals in female-only analyses simply reflected a greater statistical
power or a more robust genetic effect. The etiology of sex differences in sarcoidosis remains
unknown, but since female and male sex hormones affect the immune system in different
ways 53, one might suspect that some sex-specific genetic effects underlying sarcoidosis
risk exist. In terms of genetic risk linked with ancestry, our results suggest that focusing on
female cases may provide a more direct path toward sarcoidosis gene finding.
Consideration of phenotype plays a critical role in the search for sarcoidosis susceptibility
genes. For instance, the acute form of sarcoidosis known as Lofgren’s syndrome has a
strong association with a distinct HLA subtype 54. Other studies have shown clear
differences in genetic predisposition to acute and chronic forms of sarcoidosis 55,37. In a
reanalysis of the SAGA sib pair linkage data according to phenotype 9, we showed that
phenotypes defined by specific pulmonary manifestations of disease and affected organs had
linkage signals that were different from those based on disease status alone, but more
importantly the linkage signals we found were of greater magnitude suggesting a less diluted
genetic effect.
Persistence of radiographic defined lung disease is a sarcoidosis phenotype that appears to
have a strong association with African ancestry 15,17,56. We analyzed case subsets defined
by radiographic persistence of disease. For those with radiographic persistence, we also
analyzed the subset of cases with evidence of fibrotic (stage IV) disease. In doing so, we
found that several loci had aRRs for stage IV disease that were of greater magnitude than
any found for disease susceptibility with the strongest ancestry association signal at
chromosome 10p12.2-10q11.23 (aRR=0.27; p=0.00002). Stage IV cases were more than
three times more likely to carry two European alleles at this locus in comparison to none
(i.e. two African alleles). A recent combined genome-wide association study of Crohn’s
disease and sarcoidosis cases found the SNP with the strongest association at chromosome
10p12.2 57. The results of these phenotype-stratified analyses show the genetic
heterogeneity of sarcoidosis and the need to stratify cases into more homogeneous subsets in
gene finding efforts.
Our study had several limitations. The African-American sample we analyzed was recruited
from sites across the United States, which likely contributed to a greater variation in
European admixture proportions than would be observed if cases were drawn from a more
circumscribed geographic area 43. Although African admixture proportions varied between
28 and 99% within the study sample, variation in average African admixture was similar
across study sources. Ascertainment schemes also varied across the three source
populations, with two of the three studies ascertaining on families. In practice, having a
majority of cases with relatives allowed Mendelian inconsistent genotypes to be removed
resulting in a more accurate analytic set of genetic data. Admixture mapping cannot detect
disease variants with similar allele frequencies in the two parental populations, but disease
variants differentially fixed in the parental populations may only be detected through
admixture mapping. In addition, admixture mapping is robust to allelic heterogeneity, an
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issue that arose in trying to replicate BTNL2 associations in African-American samples 5.
The greater HLA diversity in African-Americans may have limited our ability to find
sarcoidosis linkage to this region using traditional methods, but the strong African ancestry
signal on chromosome 6p22.2 suggests African alleles in this region may indeed play a role
in sarcoidosis susceptibility.
We did find one African ancestry-disease associated locus at chromosome 6p24.3-6p12.1
that was close to the genome-wide significance level of 10−5 29 in cases with histologically
confirmed disease, but our results suggest that multiple ancestry-linked loci exist harboring
genes with alleles of both African and European origin that predispose to sarcoidosis. Next
steps will include prioritizing ancestry-linked regions for fine mapping based on level of
association and consistency of results in phenotypic subsets. While several ancestry peaks
were found at chromosomal regions where known sarcoidosis genes exist, most were in
regions that, if due to true genetic effects, may reveal novel sarcoidosis genes that help us
better understand and treat this perplexing disease. Loci identified by this ancestry scan may
also be relevant in other immune-related diseases, particularly where African-American race
is a disease risk factor. Finally, understanding the effects of ancestry on locus-specific risk
should aid in future sarcoidosis gene finding efforts in African Americans, such as genome-
wide association studies, which will attempt to isolate modest genetic effects possibly
confounded by ancestry.
MATERIALS AND METHODS
Study Sample and Case Phenotyping
DNA samples and subject data were collected from three previously conducted studies: 1) a
multi-site case control study 58; 2) a multi-site affected sib-pair study 7 and; 3) a single
institution family-based study 38. The current study, as well as the three previous studies all
underwent human subjects review with the original informed consents allowing usage of
data and genetic material for future studies. All study participants self-identified as being
African-American, with the single-institution study drawing participants from the Detroit,
Michigan area, whereas the two multi-site studies drew participants from across the United
States. Figure 2 depicts the initial sample composition submitted for genotyping and how the
final analytic sample of 1,357 sarcoidosis cases and 703 controls was derived. Of the 2,494
samples genotyped, 15 were excluded because of poor genotyping quality. Another 15
samples were excluded because the reported sex did not match genotyped sex. A total of 108
samples were found to be duplicated across studies (i.e., the same individual participated in
more than one study), and therefore the duplicate sample(s) with the poorer genotyping
quality was dropped from the analytical dataset. Nine samples were dropped due to allele-
sharing with another sample that indicated unreported monozygotic twin status. Finally, 10
samples were dropped either for having no genes of European or African ancestry or for
having evidence of the first European admixture within the last generation and, therefore,
uninformative for MALD as they posses no admixed gametes.
Among the 1,357 cases, 717 (52.8%) were members of nuclear families with one or more
sibs and/or parents genotyped. Because of the different ascertainment schemes for the two
family studies that contributed to the final analytic sample, sibships included both single and
multiple affected individuals. When available, parents were genotyped, but approximately
half of the nuclear families (50.7%) had no genotype data on parents.
The diagnostic criteria for sarcoidosis varied among the different study populations from
which the samples were derived. Overall, for an individual to be classified as a sarcoidosis
case, he or she had to satisfy the diagnostic criteria for definite or highly probable
sarcoidosis used in the SAGA study 9. In short, definite cases had histological confirmation
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of non-caseating granulomas and evidence of disease involvement in either the thorax or two
or more other organ systems. Highly probable cases lacked histologic confirmation, but had
characteristic chest radiographs (bilateral symmetrical hilar adenopathy) and either a history
of erythema nodosum or at least two years observation during which time no other disease
was found to explain radiographic abnormalities.
Where possible, cases were phenotyped as to the persistence or absence of radiographic
evidence for lung disease two years after date of diagnosis. The procurement of these data
were largely done retrospectively with the exception of a subset of cases from the ACCESS
study where study protocol dictated a two-year follow-up exam for cases recruited during
the first two years of enrollment 58. For cases that presented with a Scadding stage IV chest
radiograph (evidence of lung fibrosis or scarring), no follow-up chest x-ray was needed for
phenotyping since a stage IV x-ray indicates permanent changes. Table 6 summarizes the
demographic and clinical characteristics of the analytic sample.
Marker Panel Description
We used the Illumina Bead Station platform to assay 1,509 SNPs previously identified as
highly informative for distinguishing West African versus European ancestry. The panel of
markers is described in documentation on the Illumina website (http://www.illumina.com/
products/african_american_admixture_panel.ilmn). After performing both automated and
manual genotype calling and quality checks using the Illumina BeadStudio software, we
removed data on 49 markers with poor genotype clustering. An additional 23 markers were
removed due to a high level (>5%) of missing genotype data (n=8) or genotype frequencies
significantly different (p<10−5) than expected under Hardy-Weinberg equilibrium (n=15).
Finally, we dropped 53 markers that were in significant (p<0.0001) linkage disequilibrium
with one or more adjacent markers. This resulted in a final analytic map of 1,384 markers
with an average spacing of 2.9 cM. The median inter-marker distance was 2.4 cM with 95
percent of the markers located no farther than 7.2 cM from an adjacent SNP.
Statistical Methods
Data were analyzed using the ADMIXMAP statistical program (http://homepages.ed.ac.uk/
pmckeigu/admixmap/) 29. ADMIXMAP uses a hybrid of Bayesian and traditional modeling
to compare observed vs. expected ancestry across the genome. Both affected-only and
ancestry association (i.e., case-control) implementations were used. All models were
adjusted for age and sex. Prior allele frequencies for the African and European ancestral
populations were obtained from the International HapMap project’s 59 West AfricanYoruba
and European samples, respectively. Analyses were performed on the entire sample and on
case subsets stratified by sex, chest radiographic phenotype and disease status (i.e., definite
vs. highly probably cases).
As the current versions of admixture mapping methods do not model family data, an
unrelated set of cases and controls had to be selected for analysis. The majority of the
controls selected for the analyses were derived from the ACCESS portion of the study
sample. In addition, for families containing only unaffected sibs (due to lack of DNA from
affected individuals in the original pedigree); the unaffected sib with the oldest age of
enrollment was selected as a control. Sarcoidosis cases selected for analysis included all
ACCESS cases as well as the proband case from each family from the Henry Ford and
SAGA studies. For instances in which the proband was not genotyped (due to a lack of DNA
or removed as part of the sample quality control process), the case with the earliest age of
diagnosis was selected. Stratified analyses used the same case selection criteria (proband or
earliest age at diagnosis). This sampling procedure yielded a unique set of 1,026 cases and
316 controls for analysis.
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Analyses of mitochondrial and Y chromosomal lineages among unadmixed founders who
contributed to the African-American gene pool has shown that the female/male sex ratio was
lower in Europeans than in Africans 42,43. The average European admixture proportion is
thus lower on X chromosomes than on autosomes, since male founders contribute half as
many X chromosomes as female founders. To correctly model X chromosome admixture
proportions, we extended the statistical model to specify a global parameter ψ for the
female/male odds ratio in European versus African founders. For any given value of
autosomal admixture proportions realized by the Markov chain Monte Carlo sampler in a
given individual, the X chromosome admixture proportions can be calculated as follows. We
specify a 2 × 2 frequency table for the most recent unadmixed ancestors of the individual, in
which the rows and columns index population ancestry and sex respectively. The row
marginal frequencies are the autosomal admixture proportions and the column marginal
frequencies reflect the required equal numbers of male and female ancestors.
The cell frequencies are calculated from the odds ratio ψ and the marginal frequencies. The
X chromosome European admixture proportions are calculated as a weighted average of the
frequencies of European ancestry among females and males, with respective weights in the
ratio 2 to 1. The model is specified with a Gaussian prior for logeψ, and ψ was sampled
from its posterior distribution using a Metropolis algorithm. We allowed ψ to be estimated
from our data by specifying a weak prior (i.e., low precision) for the value of logeψ, and set
the prior mean to the null value of zero (i.e., equal proportion of male and female African
founders).
Initial analyses were conducted using the affected-only test because of its greater statistical
power, but were followed by the ancestry association test to validate affected-only test
results. Significant regions satisfied all of the following criteria: (1) at least one SNP had an
affected-only p-value < 0.01 (i.e. absolute Z-score > 2.576); (2) more than 3 SNPs had
affected-only p-values < 0.05; and (3) at least one SNP had an ancestry association p-value
< 0.05. All locus-specific Z-scores (for both ancestry association and affected-only tests),
ancestry odds ratios (aORs; estimated based on the ancestry association test), and ancestry
risk ratios (aRRs; estimated from the affected-only test) were calculated with respect to
African ancestry, with the aRRs interpreted as the ratio of the risks at the locus of interest
associated with carriage of two African alleles versus carriage of two European alleles.
Therefore, positive Z-scores and corresponding aRRs > 1 are interpretable as increased risk
associated with increased locus-specific African ancestry and negative Z-scores and
corresponding aRRs < 1 are interpretable as decreased risk associated with increased locus-
specific African ancestry (i.e. increased risk associated with increased European ancestry).
To formally test for differences in the results by sex and the extremes of the radiographic
phenotype (stage IV radiographic persistent sarcoidosis vs. radiographically resolved
disease), we computed a test of heterogeneity of the aRRs estimated from the affected-only
analyses from each stratum as the difference in the log affected-only odds ratios (θ) divided
by the information (V) for each locus. For strata A and B, the test of heterogeneity was
expressed as follows:
As with the locus specific affected-only and ancestry association tests, the test of
heterogeneity is also distributed as a standard normal deviate. P-values were two-sided for
all tests performed.
Additionally, we prepared an exclusion map for African and European risk loci based on the
affected-only test results from all sarcoidosis cases by the method described by Hoggart et
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al.29 to show which regions of the genome could be excluded from harboring a locus with a
specific aRR effect size at the traditional LOD score exclusion threshold of −2 (i.e. 100
times more likely under the null aRR of one in comparison to a specific aRR different than
one). Briefly, given the observed score and information from the affected-only test for each
SNP used in the analysis, the log-likelihood function (expressed in term of the loge(aRR))
was solved for the loge(aRR) at the value of loge(1/100) (i.e. 100 times more likely under
the null of no ancestry association). As the log-likelihood is quadratic in loge(aRR), there are
two possible values for the loge(aRR), one greater than and one less than zero. Because the
analysis was performed with respect to increased risk associated with increased locus
specific African ancestry, the value greater than zero corresponds to the exclusion threshold
loge(aRR) at or above which we can exclude an African ancestry increased risk locus, and
the value less than zero corresponds to the exclusion threshold loge(aRR) at or below which
we can exclude a African ancestry decreased risk locus or, alternatively, a European
ancestry increased risk locus.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
Genome-wide Ancestry Associations with Sarcoidosis susceptibility based on Affected-
Only and Ancestry Association Z scores.
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Figure 2.
Flow diagram of sample composition by study of origin and where samples dropped out to
form final analysis sample.
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Table 6
Demographic and Clinical Characteristics of Sarcoidosis Cases and Controls used in Admixture Mapping
Study
Full Sample Analytic Subset of Unrelateds
Factor Cases (n=1,357) Controls (n=703) Cases (n=1,026) Controls (n=316)
Age* 36.7 ± 9.7 44.0 ± 11.2 37.4 ± 9.6 41.7 ± 11.5
Male Sex 25.4% 32.7% 24.6% 28.2%
Source of Sample:
 Henry Ford 35.9% 45.9% 44.5% 9.2%
 ACCESS 18.8% 40.8% 24.9% 90.5%
 SAGA 38.7% 12.4% 24.9% 0.3%
 More than one study 7.0% 0.9% 5.8% 0.0%
Diagnostic Category:
 Definite 78.1% 84.22%
 Highly Probable 19.2% 13.8%
 Unknown 2.7% 1.9%
Chest Radiographic Follow-Up Status:
 Resolved in 2 years 23.7% 23.1%
 Persistent ≥ 2 year 48.3% 46.8%
 Stage IV 14.6% 14.7%
 Unknown 28.0% 30.1%
*Age at diagnosis for cases; Age at study enrollment for controls
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